drugset / Trial / NCT05013372
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.
Timeline
- Start
- 2023-01
- Primary completion
- 2024-01-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD147- CAR T cells | Cell therapy | 100000 cells/kg | — |
| Subject | CD147- CAR T cells | Cell therapy | 250000 cells/kg | — |
| Subject | CD147- CAR T cells | Cell therapy | 500000 cells/kg | — |
| Subject | CD147- CAR T cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | CD147- CAR T cells | Cell therapy | 2e+06 cells/kg | — |